The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II trial of two different nutritional approaches for patients receiving treatment for their advanced pancreatic cancer.
 
Diana L. Hanna
Consulting or Advisory Role - Boehringer Ingelheim
 
Gayle S. Jameson
Speakers' Bureau - Celgene
Research Funding - Celgene
 
Drew W. Rasco
Research Funding - Abbvie (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Kronos; Merck (Inst); Molecular Templates; PureTech (Inst); Seven and Eight Biopharmaceuticals (Inst); Takeda (Inst)
 
Angela Tatiana Alistar
Consulting or Advisory Role - Rafael Pharmaceuticals
Speakers' Bureau - Bristol-Myers Squibb; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Rafael Pharmaceuticals
 
Richard C. Frank
No Relationships to Disclose
 
Anthony B. El-Khoueiry
Honoraria - ABL bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; QED Therapeutics; Roche/Genentech
Consulting or Advisory Role - ABL Bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; QED Therapeutics; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca; Fulgent Genetics
 
Julia Wiedmeier
No Relationships to Disclose
 
Caroline Roberts
Employment - Virta Health
Stock and Other Ownership Interests - Virta Health
 
Brandon Fell
Employment - Virta Health
Stock and Other Ownership Interests - Virta Health (Inst)
 
Sarah Hallberg
Employment - Virta Health
Stock and Other Ownership Interests - Virta Health
Consulting or Advisory Role - Simply Good Foods
Research Funding - Virta Health
 
Denise Roe
No Relationships to Disclose
 
Derek Cridebring
No Relationships to Disclose
 
Joshua D Rabinowitz
Leadership - Farber Partners; Raze Therapeutics; Serien Therapeutics; Toran
Stock and Other Ownership Interests - Agios; Bantam Pharmaceutical; Farber Partners; Kadmon; Raze Therapeutics; Serien Therapeutics; Toran
Consulting or Advisory Role - Pfizer
Research Funding - Pfizer
Patents, Royalties, Other Intellectual Property - Princeton
 
Stephen Gately
Employment - TD2
Leadership - TD2 (Inst)
Stock and Other Ownership Interests - TD2 (Inst)
Consulting or Advisory Role - Systems Oncology
Patents, Royalties, Other Intellectual Property - TD2 (Inst)
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - AADi; Anthem Inc; CerRx; FORMA Therapeutics; Medtronic; Orpheus Bioscience; Stingray Therapeutics; Stromatis Pharma; SynDevRx; Systems Oncology; UnitedHealthcare
Consulting or Advisory Role - 7 Hills Pharma; Agastiya Biotech; Agenus; AiMed; AlaMab Therapeutics; Alpha Cancer Technologies; Amunix; Aptose Biosciences; Array BioPharma; Atalion Therapeutics; Athenex; Avesta76 Therapeutics; Axis Therapeutics; Bessor Pharma; BioXCel therapeutics; Bryologyx; CanBas; Cancer Prevention Pharmaceuticals; Caribou Biosciences; Codiak Biosciences; Coordination Pharmaceuticals; Corcept Therapeutics; CV6 Therapeutics; Cytocom; Decoy Biosystems; DNAtrix; DrugCendR; EMD Serono; Erimos Pharmaceuticals; Esperance Pharmaceuticals; EXACT Therapeutics; Fujifilm; Geistlich Pharma; Genzada Pharmaceuticals; Gimbal; GiraFpharma; GlaxoSmithKline; HUYA Bioscience International; ImaginAb; Imaging Endpoints; Immodulon Therapeutics; ImmuneOncia; Immunophotonics; Kelun; Kura Oncology; L.E.A.F. Pharmaceuticals; Lixte Biotechnology; Lycia Therapeutics; MaveriX Oncology; NeoTx; NGM Biopharmaceuticals; Nirogy Therapeutics; Northern Biologics; Novita Pharmaceuticals; Noxxon Pharma; Nucana; Oncology Venture; Oncolyze; Orphagen Pharmaceuticals; Pfizer; Phosplatin Therapeutics; RadImmune; Reflexion Medical; Reglagene; RenovoRx; Samumed; Seagen; Senhwa Biosciences; SignaBlok; Sirnaomics; SonaCare Medical; SOTIO; Strategia Therapeutics; Synergene; TD2; Tolero Pharmaceuticals; TP Therapeutics; Varian Biopharma; Verily; Vicus Therapeutics; Viracta Therapeutics; Xenter; Xerient; Xerient
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Celgene (Inst); Cleave Biosciences (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Endocyte (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Samumed (Inst); Strategia (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer